IGI Announces the Launch of Cipher, A Specialty Treaty Reinsurance Platform Focused on Cyber

International General Insurance Holdings Ltd. ("IGI" or the "Company") (NASDAQ: IGIC), the international specialty insurance and reinsurance group, today announced the launch of Bermuda-based Cipher ...
Yahoo Finance

Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors

Next-generation multispecific antibody, ISB 2301, targets 3 tumor-associated antigens (TAAs) and activates both T cells and natural killer (NK) cells ISB 2301 is rapidly advancing toward the clinic; ...
Bernews

IGI Launch Bermuda-Based Cipher Underwriting

International General Insurance Holdings Ltd. [IGI] announced the launch of Bermuda-based Cipher Underwriting Ltd, a ...
Reinsurance News

IGI launches Bermuda-based specialty treaty reinsurance MGA, Cipher

International General Insurance Holdings Ltd. (IGI) has announced the launch of Bermuda-based Cipher Underwriting Ltd., a ...
MarketWatch

(PR) Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 /PRNewswire/ -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today ...
GEN

AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+

AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, now in development against multiple myeloma, ...
manilatimes

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) ...